Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 15, 2006 Selena Maranjian	My Dividends Are Bigger Than Yours Your yield may be 2% when mine is a whopping 13%. Here's the secret.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool January 10, 2007 John Reeves	Is Your Stock a Dog? A dividend yield can be a very misleading ratio, and when it comes to identifying stable companies that deliver regular and growing cash flows, you must look deeper than just a single metric.
The Motley Fool August 28, 2010 Todd Wenning	Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test?
The Motley Fool December 18, 2008 Selena Maranjian	Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool May 3, 2007 Joe Magyer	The Weekly Dividend Could your portfolio use a Band-Aid? PepsiCo... Arch Coal... Dow Chemical... Johnson & Johnson... etc.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool July 13, 2011	Roundtable: Can You Retire on These Stocks? Motley Fool writers weigh in with their opinions on the best and worst stocks for retirement portfolios.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool June 11, 2008 Brian Orelli	Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Diageo Is Attractive? Among spirits companies, Diageo stacked up well against some competitors.
The Motley Fool October 25, 2005 Selena Maranjian	Is Biggest Best? Even giant companies can be volatile. Don't be complacent with blue chips. It's never smart to look at just one factor for any company. To have the best chance of doing well, you need to study a company closely, evaluating its health and prospects from many angles.
The Motley Fool September 2, 2005 Nathan Parmelee	3 Stocks That Can Pay More Dividend growth is as important as the dividend itself. Here are three stocks that make the dividend growth cut. Polaris Industries... Nokia... Kimberly-Clark...
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool January 18, 2011 Russ Krull	Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold?
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool June 27, 2008 Ryan Fuhrmann	Recession-Proof Stocks: Johnson & Johnson This industry titan's stock is beaten down and should recover quite nicely when headwinds stop working against it and start to shift toward its back.
The Motley Fool March 24, 2008 Todd Wenning	What's Killing Your Retirement For retirees and those approaching retirement, the state of the market must be terrifying. Read on for one way to maintain your asset base during a market storm.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years.
The Motley Fool May 11, 2009 Selena Maranjian	How I'm Grabbing 20% Dividend Yields While the current yield on a stock might be only 2 or 3%, for those who bought it long ago at a lower price, and who are getting that same current dividend, their effective yield is higher. And over time, it can grow very high indeed.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool January 4, 2012 Rebecca Lipman	Trading Strategy: 2012 Dogs of the Dow Are any of these names in your portfolio -- or on your watch list?
The Motley Fool March 28, 2008 Selena Maranjian	His Dividends Are Bigger Than Mine Buy into healthy, growing, dividend-paying companies -- and then hang on to them.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
The Motley Fool January 8, 2009 Jeff Fischer	5 Stocks for Strong Income Boost your returns in any market with these stocks: 3M... Johnson & Johnson... McCormick & Co. ... PepsiCo... Conoco Phillips...
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool March 25, 2010 Anand Chokkavelu	Your Next Big Dividend Stock These are some really good candidates: Merck... ConAgra Foods... Johnson & Johnson... Marathon Oil... Sysco... FPL Group... McDonald's...
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.
The Motley Fool February 18, 2005 W.D. Crotty	Diageo: Cash, Dividends on Tap This adult-beverage company puts up some very impressive numbers. The stock is up almost 2% to $57.50 a share today.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool February 27, 2009 Alex Dumortier	GE's Dividend Head-Fake General Electric CEO Jeffrey Immelt announces that the company will cut its dividend by two-thirds, a move that will produce significant cash savings and also be a gesture of goodwill toward the credit rating agencies that are reviewing GE's rating.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool May 12, 2010 Matt Koppenheffer	Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround?